Search Videos and More

Showing 1 - 12 of 55 results

Previous| 1 | 2 | 3 ...5 |Next


Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives News

Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives

Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.
Researchers Devise Novel Solution to Preventing Relapse after CAR T-cell Therapy News

Researchers Devise Novel Solution to Preventing Relapse after CAR T-cell Therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.
Researchers Customize AI Tools for Digital Pathology News

Researchers Customize AI Tools for Digital Pathology

Scientists from Dana-Farber Cancer Institute and Weill Cornell Medicine have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a relatively new field that uses high-resolution digital images that are created from tissue samples to diagnose diseases and inform treatment decisions.
Study Highlights the Importance of Infection Prevention After CAR T-Cell Therapy News

Study Highlights the Importance of Infection Prevention After CAR T-Cell Therapy

A systematic review and meta-analysis of non-relapse mortality after CAR T-cell therapy.
Dana-Farber Researchers Discover New Target for Potential Leukemia Therapy News

Dana-Farber Researchers Discover New Target for Potential Leukemia Therapy

A team of Dana-Farber Cancer Institute investigators discovered that a subset of myeloid and lymphoid leukemias depend on a molecular complex called PI3Kgamma for survival.
Unraveling the Menin Mystery to Halt Cancer Growth News

Unraveling the Menin Mystery to Halt Cancer Growth

The story of research in menin and its relation to cancer — from early efforts to understand how the cell makes use of menin, to explorations of the cell machinery operated by menin, to the development and testing of agents that inhibit menin, to work on preventing resistance to such agents — weaves through Dana-Farber at every step.
Ancient DNA Reveals Origin of Racial/Ethnic Disparity in a Childhood Cancer News

Ancient DNA Reveals Origin of Racial/Ethnic Disparity in a Childhood Cancer

There are 40% more Hispanic/Latino kids diagnosed with acute lymphoblastic leukemia (ALL) than white non-Hispanic/Latino children; actually, Hispanic/Latino individuals have the highest risk of ALL in the United States. However, the basis for this difference is not well understood. Researchers recently identified a genetic variant that accounts for the increased risk of B-cell ALL in Hispanic/Latino children, and using ancient DNA, they traced the mutation all the way back to the first migrants who entered the Americas ~13,000 years ago.
Bispecific Antibody Therapies for Lymphoma News

Bispecific Antibody Therapies for Lymphoma

Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody therapies have been FDA approved with more on the horizon. These are exciting new medicines that rally the immune system in a powerful way to fight blood cancers. But rolling out a new type of medicine is a project of its own.
BCL2 Inhibitors: What’s the Latest Research? News

BCL2 Inhibitors: What’s the Latest Research?

BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) in adults.
Dana-Farber CEO Laurie Glimcher Has Always Been a Trail-Blazer and a Risk-Taker News

Dana-Farber CEO Laurie Glimcher Has Always Been a Trail-Blazer and a Risk-Taker

Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.
Antibody-Drug Conjugates: A Cancer Therapy Revolution News

Antibody-Drug Conjugates: A Cancer Therapy Revolution

Dana-Farber researchers explore how a novel therapy may benefit patients
Exploring How CAR T-Cell Therapy May Help More Patients News

Exploring How CAR T-Cell Therapy May Help More Patients

CAR T-cell therapy burst onto the scene as a revolutionary treatment for cancer patients in 2015, when it was introduced in clinical trials primarily for patients with lymphoma and leukemia. Since then, it has transformed the course of disease, primarily for blood cancer patients, with many clinical trials now exploring the approach for solid tumor patients. Through this highly tailored form of immune effector cell (IEC) therapy, typically a patient's own immune cells — known as T cells — are genetically re-engineered to identify and kill cancer cells.

Showing 1 - 12 of 55 results

Previous| 1 | 2 | 3 ...5 |Next